AR and prostate carcinoma: This dependence on AR makes localized prostate cancer highly sensitive to blockading AR signaling by drugs that target DHT production, such as LH-RH agonists, or CYP17A1 inhibitors, such as abiraterone acetate, or drugs directly inhibiting the AR such as enzalutamide, darolutamide, or apalutamide.